Champions Oncology ( (CSBR) ) has released its Q4 earnings. Here is a breakdown of the information Champions Oncology presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Champions Oncology, Inc. is a global preclinical and clinical research services provider specializing in oncology R&D solutions, offering innovative data through proprietary platforms to advance drug discovery and development.
In its latest earnings report, Champions Oncology announced a record annual revenue of $57 million for fiscal year 2025, marking a 14% increase from the previous year. The company also reported a return to profitability with a net income of $4.6 million, highlighting a successful financial turnaround.
Key financial metrics included a fourth-quarter revenue of $12.3 million, despite a 12% decline compared to the same period last year. The company achieved an adjusted EBITDA income of $7.1 million for the fiscal year, a significant improvement from the previous year’s loss. Strategic initiatives such as the launch of a high-margin data business contributed to these results, alongside operational efficiencies that reduced costs and improved margins.
Looking ahead, Champions Oncology’s management expresses confidence in continued revenue growth and further monetization of its data offerings, supported by a strong pipeline as they enter fiscal 2026. The company aims to build on its momentum through disciplined execution and scalable growth strategies.